Replimune Group, Inc. (REPL): Total Liabilities
$166.23M
As of 2026-03-31
$146.80M
As of 2026-06-30
+22.1%
3-year compound annual growth
+30.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $166.23M | +22.7% | 2026-06-29, Balance as of period end |
| 2025-03-31 | $135.49M | +19.7% | 2026-06-29, Balance as of period end |
| 2024-03-31 | $113.21M | +24.0% | 2025-05-22, Balance as of period end |
| 2023-03-31 | $91.30M | +82.7% | 2024-05-16, Balance as of period end |
| 2022-03-31 | $49.96M | +12.6% | 2023-05-18, Balance as of period end |
| 2021-03-31 | $44.37M | -11.9% | 2022-05-19, Balance as of period end |
| 2020-03-31 | $50.38M | +205.9% | 2021-05-20, Balance as of period end |
| 2019-03-31 | $16.47M | +140.2% | 2020-06-03, Balance as of period end |
| 2018-03-31 | $6.86M | n/a | 2019-06-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Replimune Group, Inc. (REPL) | 2026-03-31 | $166.23M | +22.7% |
| Prokidney Corp. (PROK) | 2025-12-31 | $34.78M | -11.8% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $221.87M | +53.7% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $96.38M | +8.5% |
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $194.15M | +4.8% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $102.49M | -23.3% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $21.54M | +92.0% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $576.73M | +101.9% |
| Kyverna Therapeutics, Inc. (KYTX) | 2025-12-31 | $61.55M | +61.7% |
Compare REPL, PROK, PRME, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗